#NewsAlert: Today, we reported our fourth quarter and full year 2024 financial results and provided a business update. We are off to a strong start with the U.S. launch of Revuforj® (revumenib) and are very encouraged by the early patient demand and breadth of prescribing, as well as the favorable coverage from payers. With two first-in-class medicines on the market that address major unmet needs and a robust development strategy underway, Syndax is well-positioned for long-term success. Learn more by reading our full release and joining us on our conference call today at 8:00 a.m. ET: https://lnkd.in/gXEkPJqB A live replay will be available for a limited time.
